This collaboration aims to expedite the development and commercialization of LaNova’s promising drug pipeline, including the groundbreaking LM-108 monoclonal antibody targeting multiple cancers. The ...
The deal allows Merck to take over development of privately held LaNova Medicines' LM-299, the companies said on Thursday.
Pharmaceutical Technology on MSN5d
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
SINO BIOPHARM (01177.HK) injected its capital to the equity interests of LaNova Medicines with its self-raised funds, and ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback